How's Moderna doing these days?
In our biotechnology market deck, you will find everything you need to understand the market
SUMMARY
How's Moderna doing these days? Moderna is doing better than the easy bear case, but the company is still not fully repaired.
The cleanest way to read Moderna now is as a disciplined turnaround biotech, not as a stable vaccine franchise. The company has enough cash and enough catalysts, but it still needs new products to replace the COVID-era revenue base.
The cash burn is still large, but the direction has changed. Q1 2026 showed a $1.3 billion net loss, yet R&D fell 24% year over year, SG&A fell 18%, and management is clearly shrinking the company around fewer bets.
The 2028 breakeven target is plausible, but it is not yet proven. Moderna’s Ares credit facility gives it more flexibility, while the milestone-linked structure also reminds us that lenders are not treating the next few years as low risk.
Regulatory momentum is becoming geographically uneven. Europe looks constructive for Moderna’s respiratory portfolio, while the U.S. FDA’s flu filing reversal shows that approval timing can still shift quickly and messily.
The flu vaccine is not dead, but the simple launch story is gone. The amended U.S. filing and August 5, 2026 decision date keep the program alive, yet the older-adult pathway now carries extra friction.
The cancer vaccine is the strongest reason to keep watching Moderna. Five-year melanoma data with Merck’s Keytruda showed durable benefit, which makes the oncology story harder to dismiss than a normal early-stage biotech signal.
The CMV failure matters because it weakened the broad “mRNA platform solves everything” story. Moderna now has to prove each product on its own merits, which is less glamorous but probably healthier.
RSV gives Moderna a real product, but not a recovery engine. GSK and Pfizer moved first, Moderna’s early uptake was small, and the RSV category itself has cooled since the initial launch wave.
U.S. vaccine politics remain a major risk even though Moderna is more international now. Around 80% of Q1 2026 revenue came from international markets, but FDA decisions, HHS funding choices, and BARDA’s mRNA pullback still shape investor confidence.
The patent settlement was expensive but useful. Paying $950 million upfront hurt cash, yet removing an open-ended lipid-nanoparticle legal overhang gave investors a cleaner view of the pipeline.
The most important pattern is that Moderna’s good news now comes with next-proof-needed attached. Cost cuts need revenue, flu needs approval, RSV needs uptake, and oncology needs Phase 3 confirmation.
So the answer is pretty clear: Moderna is alive, more focused, and more credible than it looked after the COVID collapse, but the next 12 to 24 months will decide whether this becomes a real second act or just a cleaner decline.
This market map, featured in our biotechnology market deck, highlights top companies and startups in the biotechnology market
Is Moderna still burning too much cash now?
Moderna is still burning a lot of cash today.
The freshest financial signal comes from Moderna’s Q1 2026 results in May 2026. Revenue was about $389 million, while the GAAP net loss was $1.3 billion. Part of that loss came from the Arbutus/Genevant patent settlement charge, but even adjusting for that, the company is still running a very expensive machine for a business whose COVID-era revenue base has disappeared.
What makes the situation less alarming than it looked a year ago is the cost direction.
In that same Q1 2026 update, R&D expense fell 24% year over year and SG&A fell 18%. Moderna also kept guiding to lower operating expenses in 2026, and the July 2025 layoff plan showed the cuts were not just spreadsheet language. Stéphane Bancel told employees the company would reduce its workforce by about 10% and end 2025 with fewer than 5,000 employees.
So it looks like the cash burn is no longer being hidden behind “platform investment” language.
Moderna is visibly shrinking the company around fewer bets. Still, the burn remains big: the company had $7.5 billion in cash and investments at the end of Q1 2026, down from $8.1 billion at the end of 2025, and it still expects to end 2026 with $4.5 billion to $5.0 billion after the patent settlement payment. That is enough runway, but not comfort.
At the end of the day, Moderna currently has time, not freedom. It has enough cash to reach the next major readouts, but the company still needs the pipeline to start paying back before 2028.
If you want more recent data on this point, please see our latest biotechnology market report.
Is Moderna’s 2028 breakeven target actually believable now?
Moderna’s 2028 breakeven target is believable as a plan, but not yet as a fact.
The company has been very explicit about the path: up to 10% revenue growth in 2026, lower operating expenses, a broader seasonal vaccine portfolio, and cash breakeven by 2028. At its November 2025 strategy update, Moderna framed the next few years around seasonal vaccines funding oncology and rare disease work, rather than trying to keep every possible mRNA program moving at once.
The weak signal is the financing structure. Around that strategy update, Moderna secured a five-year credit facility of up to $1.5 billion from Ares. The details matter: the facility was split into tranches, with later access partly tied to regulatory milestones. That is a subtle but important message. Lenders are giving Moderna flexibility, but not pretending the next few years are risk-free.
Analysts have also stayed cautious. Coverage after the plan suggested that some investors still see 2028 as too early, with breakeven more likely around 2029 or 2030 unless more cuts happen or revenue ramps faster than expected. That skepticism is fair. Moderna is still guiding to about $3.0 billion of R&D expense and $1.0 billion of SG&A in 2026, which is heavy for a company still rebuilding revenue.
The breakeven story is credible but fragile.
As this chart shows, and as featured in our biotechnology market deck, search interest in biotech has been trending upward
Is Moderna getting regulatory momentum again these days?
Moderna has real regulatory momentum outside the U.S., while the U.S. has become much more unpredictable.
Europe has been surprisingly constructive lately. In Q1 2026, Moderna pointed to EU approvals for mNEXSPIKE, its next-generation COVID vaccine, and mCOMBRIAX, its flu-plus-COVID combination vaccine. It also highlighted the broader European approval of mRESVIA for adults aged 18 and older. That gives Moderna a much fuller respiratory shelf in Europe than the stock market often seems to price in.
The U.S. looks very different. In February 2026, the FDA first refused to review Moderna’s mRNA flu vaccine application, then accepted an amended filing roughly eight days later after Moderna changed the age-based approval approach. That reversal was good news, but the episode itself was a warning. The FDA did not say the vaccine had failed on safety or efficacy. The issue was actually the comparator design in older adults. For a vaccine company, that kind of late procedural surprise can change launch timing and commercial planning.
The broader policy backdrop makes this even more important. In August 2025, HHS announced a wind-down of BARDA-backed mRNA vaccine development, affecting 22 mRNA-related projects. Moderna later saw its pandemic flu funding replaced partly by CEPI support, not by the U.S. government. That is a major change from the COVID period, when U.S. public funding helped turn Moderna into a global company.
All things considered, Moderna can still get vaccines reviewed and approved, but the U.S. is no longer an easy accelerant for its mRNA vaccine strategy. Today, Europe looks like the more predictable respiratory market.
If you want more recent data on this point, please see our latest biotechnology market report.
Is Moderna’s flu vaccine still alive now?
Moderna’s flu vaccine is alive, but the U.S. launch story has become more complicated.
The February 2026 FDA refusal-to-file looked bad at first because it hit the exact product Moderna needs for its seasonal vaccine rebuild. The company had enrolled more than 40,000 adults in late-stage flu vaccine trials, yet the FDA objected to the comparator used for older adults. That is not a small technicality when the senior population is one of the most commercially important flu vaccine groups.
The quick reversal matters. After a Type A meeting, the FDA accepted an amended application and set an August 5, 2026 decision date. Moderna is now pursuing full approval for adults aged 50 to 64 and accelerated approval for adults 65 and older, with a post-marketing study commitment. That tells us the program is not dead, but it also tells us the original clean launch path is gone.
The interesting comparison is with Europe, Canada, and Australia, where Moderna had already said the flu application was accepted for review. So the product problem and the U.S. process problem are not the same thing. The vaccine may still be commercially useful, but the U.S. pathway now carries more friction.
Moderna’s flu vaccine still matters a lot, but it is no longer a smooth approval story.
This chart, featured in our biotechnology market deck, illustrates yearly venture capital funding for biotechnology startups
Is Moderna’s cancer vaccine becoming the real story again?
Yes, Moderna’s cancer vaccine is currently the best reason to keep paying attention to the company.
The June 2026 ASCO update from Moderna and Merck was stronger than a normal biotech conference headline. At five years of follow-up, intismeran autogene plus Keytruda showed a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death versus Keytruda alone in high-risk melanoma. The important part is not just the percentage but that the benefit held up at a median follow-up of about five years.
That durability changes the quality of the signal. A small early oncology study can always look exciting. A personalized cancer vaccine still showing a similar recurrence-free survival benefit after five years is much harder to dismiss. Fierce Biotech also pointed out that the recurrence-risk reduction had already been 49% at the three-year analysis and remained 49% at five years, which is exactly the kind of consistency investors want to see before Phase 3 data.
The program is also no longer just one melanoma experiment. Moderna and Merck now have nine Phase 2 and Phase 3 trials underway across melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma. The adjuvant melanoma Phase 3 study is fully enrolled, a renal cell carcinoma Phase 2 study is fully enrolled, and Moderna recently initiated a Phase 3 study in high-risk Stage I non-small cell lung cancer.
If you want more recent data on this point, please see our latest biotechnology market report.
Did Moderna’s CMV failure hurt the platform story recently?
Yes, the CMV failure made it harder to believe in Moderna’s platform on faith alone.
In October 2025, Moderna said its Phase 3 CMV vaccine did not meet the primary efficacy endpoint in seronegative women of childbearing age. The company then discontinued the congenital CMV program. That was a big deal because CMV had been one of the most important non-COVID proof points in Moderna’s infectious-disease pipeline.
The lesson is that mRNA does not automatically solve difficult vaccine biology. CMV was supposed to show that Moderna could take the same platform logic beyond respiratory viruses into a large unmet-need vaccine category. Instead, it became a reminder that each indication still needs its own clinical proof.
That failure also helps explain the sharper focus we see now. In Q1 2026, Moderna said lower R&D spend partly reflected the wind-down of respiratory and CMV studies. The company is no longer behaving like every platform extension deserves equal funding. Instead, it is choosing the programs with the clearest near-term clinical or commercial payoff.
CMV hurt the broad platform narrative. But it may also have forced Moderna into a healthier discipline: fewer stories, more evidence.
This chart, featured in our biotechnology market deck, looks at Vertex’s strategy in biotechnology
Is Moderna still behind in RSV these days?
Moderna is still behind in RSV, even though mRESVIA gives it a legitimate product.
The RSV market moved faster than Moderna. GSK’s Arexvy and Pfizer’s Abrysvo got to market first, and early commercial expectations were much larger for those two products than for Moderna’s mRESVIA. A 2024 market snapshot cited combined first-year revenue above $2.4 billion for GSK and Pfizer’s RSV shots, while analyst expectations for Moderna’s first RSV season were far smaller.
The more recent data still does not show a breakout. Market research published in 2025 estimated Moderna’s early mRESVIA sales at only around $20 million to $30 million, with very limited uptake in the first half of 2025. Moderna did get an important FDA expansion in June 2025 for adults aged 18 to 59 who are at increased risk, and Europe also broadened the product’s approval. That improves the label, but label expansion is not the same as share capture.
The bigger problem is that the RSV category itself has cooled. Recent market estimates suggest the global RSV vaccine market could decline from roughly $1.15 billion in 2025 to under $1.0 billion in 2026 and keep shrinking over time. That may be too pessimistic, but it matches what we have seen commercially: the category launched with excitement, then ran into CDC guidance, seasonality, and slower revaccination behavior.
At the end of the day, RSV helps Moderna look broader, but it is not carrying the recovery. The company’s seasonal upside now depends much more on flu, next-generation COVID, and combination vaccines.
Is Moderna less exposed to U.S. vaccine politics now?
Moderna is less dependent on the U.S. than before, but it is still very exposed to U.S. vaccine politics.
The international shift is real. In Q1 2026, Moderna said about 80% of revenue came from international markets. The UK is one of the more interesting signals: Moderna delivered its first shipment under its long-term UK strategic partnership, and its Harwell manufacturing and R&D facility became fully operational in 2025. That gives the company a real non-U.S. public-health infrastructure story, not just export revenue.
The CEPI bird flu funding is another subtle signal. After HHS walked away from mRNA pandemic flu support, CEPI stepped in with up to $54.3 million to help move Moderna’s H5 pandemic influenza vaccine into Phase 3. Moderna then launched a large trial with roughly 4,000 adults in the U.S. and UK. That shows the platform still has global public-health value, even when Washington is pulling back.
But the U.S. remains too important to shrug off. FDA decisions affect launch timing, labels, payer behavior, and investor confidence. HHS’s BARDA wind-down also tells every vaccine investor that mRNA respiratory programs may face less public funding and more political scrutiny in the U.S. than they did during COVID.
So the company is diversifying, but not escaping. Moderna’s international partnerships are becoming a real buffer, while U.S. vaccine politics remain one of the biggest risks around the stock.
If you want more recent data on this point, please see our latest biotechnology market report.
This chart, featured in our biotechnology market deck, illustrates yearly funding for biotechnology startups
Did Moderna’s patent settlement actually help recently?
Yes, the patent settlement helped Moderna because investors cared more about removing uncertainty than about the headline cost.
In March 2026, Moderna agreed to pay $950 million upfront to settle global patent litigation with Arbutus and Genevant. The settlement also includes a possible additional $1.3 billion payment depending on the government-contractor immunity appeal. On the surface, that is a painful amount of money for a company still burning cash.
The market reaction tells us why it was still good news. Moderna’s stock jumped about 16% after the deal, because analysts had been thinking about much larger downside scenarios, reportedly around $5 billion in protected liability in some cases. The deal also removed future royalty obligations and covered Moderna’s broader infectious-disease portfolio, including Spikevax, mRESVIA, mNEXSPIKE, mCOMBRIAX, and future vaccines.
That last point matters more than it sounds. If Moderna wants seasonal vaccines to fund oncology, investors need to know future vaccine revenue will not be dragged down by an unresolved lipid-nanoparticle royalty fight. The settlement turned a scary open-ended legal problem into a known cash hit.
So, finally, the settlement was ugly but useful. Moderna paid a lot, but it bought clarity at exactly the moment it needed investors to focus on pipeline catalysts again.
Is Moderna’s leadership acting like the company is pivoting?
Yes, Moderna’s leadership moves look like a company moving from platform expansion to late-stage execution.
The most telling hire was David Berman, who joined as Chief Development Officer in March 2026. His background is not generic biotech management. He came with deep oncology and immunotherapy experience from Immunocore, AstraZeneca, and Bristol Myers Squibb, including senior work on clinical-stage immunotherapies. At the same time, Jacqueline Miller stepped down as Chief Medical Officer after a little more than a year in the role.
That matters because Moderna’s most important value driver now is probably something like “can we run late-stage development well enough to turn the Merck cancer vaccine into an approved product?”. Berman’s profile fits that problem much more directly than a broad vaccine-development profile would.
The workforce cuts point in the same direction. The July 2025 layoff note from Bancel was unusually direct: fewer than 5,000 employees by year-end, roughly 10% fewer workers, and a broader plan to reduce annual operating expenses by about $1.5 billion by 2027. BioPharma Dive estimated the cuts would affect more than 800 employees, which makes this a real operating reset, not a soft hiring slowdown.
So it looks like Moderna is becoming a more conventional late-stage biotech again.
If you want more recent data on this point, please see our latest biotechnology market report.
This chart, featured in our biotechnology market deck, compares the main business model options for biotech platform companies
Is the market starting to trust Moderna again?
The market is giving Moderna another chance, but it is still treating the company like a catalyst trade.
As of mid-June 2026, Moderna trades around $52 per share, with a market cap around $20.6 billion and a negative P/E because the company is still loss-making. That valuation is interesting: investors are not pricing Moderna like a dead COVID stock, but they are also not treating it like a stable vaccine franchise.
The stock reactions tell the story better than the level. Moderna jumped after the patent settlement because the downside case became less scary. It reacted positively when the FDA accepted the amended flu filing because one key seasonal vaccine route reopened. It also benefited from the stronger oncology narrative after the five-year ASCO data. These are all event-driven moves, not signs of deep trust.
Analyst behavior still looks cautious. The recurring questions are cash burn, 2028 breakeven credibility, whether RSV can ever matter, whether U.S. vaccine policy gets worse, and whether Phase 3 oncology can confirm the Phase 2b signal. That is exactly what you would expect when a company has strong science but weak current earnings.
Moderna is investable again for people who believe in the next catalysts.
So, how is Moderna doing these days?
Moderna is doing better than the simple bear case, but the recovery is still unfinished.
The company has made real progress recently. It cut costs, preserved enough cash, removed a major patent overhang, got important European vaccine approvals, kept its flu program alive in the U.S., and delivered genuinely strong five-year cancer vaccine data with Merck. Those are not small signals. They are enough to say Moderna is no longer just drifting after COVID.
The problem is that almost every good signal still comes with a “next proof needed.” Cost cuts need revenue. Flu needs FDA approval. Combination vaccines need U.S. clarity. RSV needs real uptake. Oncology needs Phase 3 confirmation. International partnerships help, but U.S. vaccine politics still matter a lot.
Moderna is a disciplined turnaround biotech with one very exciting oncology option and one still-fragile respiratory vaccine bridge.
The company is alive, serious, and more focused than before, but the next 12 to 24 months will decide whether this becomes a real second act or just a cleaner version of the post-COVID decline.
| Question | Answer | What supports it |
|---|---|---|
| Is Moderna still burning cash now? | Yes, but it is finally cutting hard enough for the burn to look managed. | Q1 2026 showed a $1.3B net loss, $7.5B cash/investments, R&D down 24%, SG&A down 18%, and a 2025 workforce reduction of about 10%. |
| Is 2028 breakeven believable now? | It is believable as a plan, but still fragile. | Moderna still targets 2028 cash breakeven, but took a $1.5B Ares facility and still expects about $4B of 2026 R&D plus SG&A. |
| Is regulatory momentum back? | Outside the U.S., yes. In the U.S., it is much less predictable. | EU approvals for mNEXSPIKE, mCOMBRIAX, and broader mRESVIA contrast with the FDA’s February 2026 flu refusal-to-file episode. |
| Is Moderna’s flu vaccine alive? | Yes, but the clean launch path is gone. | The FDA accepted the amended filing after initially refusing review and set an August 5, 2026 decision date. |
| Is cancer the real story again? | Yes, this is Moderna’s strongest upside signal today. | Five-year ASCO data showed 49% lower recurrence/death risk and 59% lower distant metastasis/death risk with Merck’s Keytruda. |
| Did CMV hurt the platform story? | Yes, it made product-by-product proof much more important. | The October 2025 Phase 3 CMV miss led Moderna to discontinue the congenital CMV program. |
| Is Moderna still behind in RSV? | Yes, RSV looks more like portfolio filler than a growth engine. | GSK and Pfizer entered first, Moderna’s early mRESVIA sales were small, and the RSV market has cooled after the first launch wave. |
| Is U.S. vaccine politics still a risk? | Yes, even with more international revenue. | 80% of Q1 2026 revenue was international, but HHS wound down BARDA mRNA support and Moderna needed CEPI help for bird flu. |
| Did the patent settlement help? | Yes, because clarity mattered more than the $950M payment. | The deal removed global litigation, future royalties, and a feared larger liability; the stock rose sharply after the announcement. |
| Is leadership really pivoting? | Yes, the team now looks built for late-stage oncology and cost control. | David Berman joined as CDO, the CMO stepped down, and the company cut about 10% of employees. |
| Is the market trusting Moderna again? | Partly, but mostly through catalysts. | The stock reacts strongly to legal, FDA, and oncology updates, while earnings remain negative and analysts still question breakeven timing. |
OUR METHODOLOGY
This analysis tests how Moderna is doing today by looking across the main dimensions that shape the company’s outlook: cash burn, breakeven credibility, regulatory momentum, flu, oncology, CMV, RSV, policy exposure, legal risk, leadership changes, and market trust.
The answer is not obvious from one headline, one stock move, or one financial metric. We therefore used structured signal aggregation to separate evidence-backed progress from areas where the Moderna story still needs more proof.
For each dimension, we prioritized recent signals: company updates, regulatory decisions, clinical readouts, funding changes, partnership developments, litigation outcomes, leadership changes, cost actions, and market reactions.
When we discuss cash burn, we rely mainly on Moderna’s Q1 2026 financial results, its reported cash and investment balance, its 2026 expense guidance, and its announced cost-reduction plan. This is why the analysis treats Moderna as still burning heavily, but no longer pretending the old cost structure can continue unchanged.
When we discuss breakeven, we treat Moderna’s 2028 target as management’s plan, not as a proven outcome. The Ares credit facility is used as a financing signal because it gives Moderna flexibility while also showing that future access to capital can depend on milestones.
When we discuss regulation, we separate Europe from the U.S. because the signals are now different. European approvals for mNEXSPIKE, mCOMBRIAX, and mRESVIA suggest momentum, while the FDA’s flu refusal-to-file episode and later amended acceptance show a more unpredictable U.S. process.
When we discuss oncology, we put extra weight on the five-year Moderna/Merck intismeran autogene plus Keytruda melanoma data because durability matters more than a short-lived early oncology signal. The analysis also considers the broader Phase 2 and Phase 3 trial footprint across melanoma, lung cancer, bladder cancer, and renal cell carcinoma.
When we discuss platform risk, we include the CMV Phase 3 miss because it directly challenges the idea that mRNA platform logic automatically transfers across indications. The CMV discontinuation is treated as an important evidence point, not just a pipeline cleanup.
When we discuss RSV and respiratory vaccines, we compare product approval with commercial traction. A broader label helps Moderna’s portfolio story, but early mRESVIA uptake, first-mover competition from GSK and Pfizer, and a cooling RSV category make it hard to treat RSV as the recovery engine.
When we discuss policy exposure, we look at both sides of the geographic shift. International revenue, the UK partnership, Harwell, and CEPI support show Moderna has a real non-U.S. buffer, while HHS’s BARDA mRNA wind-down and FDA uncertainty keep U.S. vaccine politics central to the risk case.
When we discuss legal risk, we treat the Arbutus/Genevant patent settlement as a clarity event. The upfront payment hurt cash, but the removal of global litigation, future royalties, and a potentially larger liability made the pipeline easier for investors to value.
This structured aggregation is what makes the final answer clearer. Moderna is not simply a failed COVID winner, but it is also not yet a fully repaired vaccine and oncology company. The conclusion comes from reading the recent signals together, rather than treating any single approval, trial result, cost cut, or stock reaction as the whole story.
We are not affiliated with Moderna, Merck, or any other company mentioned in this analysis. We do not hold shares in Moderna. Nothing here should be read as investment advice, a recommendation to buy or sell any security, or a substitute for independent financial research.
Key sources used for this analysis include: Moderna Q1 2026 financial results and business update, Moderna Q1 2026 financial results press release, Moderna’s five-year credit facility with Ares Management, Moderna’s European Commission authorization for mCOMBRIAX, EMA’s product page for mRESVIA, Fierce Biotech on FDA acceptance of Moderna’s amended flu vaccine filing, MarketWatch on the FDA acceptance and August 2026 decision date, The Washington Post on the FDA refusal to review Moderna’s flu vaccine application, Merck on five-year intismeran autogene plus Keytruda melanoma data, Fierce Biotech on five-year Moderna/Merck cancer vaccine data, Moderna’s Phase 3 CMV vaccine readout reflection, FDA’s product page for mRESVIA, HHS on the BARDA mRNA vaccine development wind-down, CEPI funding for Moderna’s H5 pandemic influenza Phase 3 trial, Moderna’s initiation of the Phase 3 H5 pandemic influenza vaccine study, Moderna’s global patent litigation settlement with Arbutus/Genevant, Genevant and Arbutus on the settlement, MarketWatch on Moderna’s stock reaction to the patent settlement, Moderna’s announcement of David Berman as Chief Development Officer, Stéphane Bancel’s July 2025 workforce reduction note, and BioPharma Dive on Moderna layoffs and expense cuts.
This chart, featured in our biotechnology market deck, breaks down revenue across customer segments in the biotechnology market
Related blog posts
- How strong is fundraising in the biotechnology market right now?
- The startups that have raised the most funding in the biotechnology market
- The most highly valued startups in the biotechnology market
- BioTech: what are the current investments trend?
- Where is the money now in the BioTech market?
